ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013 ARIAD Pharmaceuticals, Inc. In split studies, ponatinib is shown to inhibit RET, a clinically proved oncogenic driver of medullary thyroid cancers and non-little cell lung cancer , and FGFR, which is commonly mutated in endometrial, lung and various other cancers. The potency of ponatinib was found to considerably exceed that of other authorized tyrosine kinase inhibitors with RET activity http://viagrauk.net . These total results provide strong support for the clinical evaluation of ponatinib in patients with RET-driven cancers. The unique design features that enable ponatinib to overcome mutation-based resistance in CML, including the gatekeeper mutation, also connect with its activity against its additional tyrosine kinase targets including RET, KIT and FGFR, mentioned Timothy P.
Both models are designed to give a customized user experience with on-board computers and movement sensors that restore self-initiated walking without needing tethers or switches to begin with movement.. YASKAWA provides made a significant capital investment in to the ReWalk exoskeleton technology and will also serve as the unique distributor for the ReWalk in Japan, China, Singapore, Taiwan, Thailand, and Korea. The new financing and partnership with YASKAWA can help progress the ReWalk infrastructure and technology for users and support business growth with the expansion of research and development and enhanced design to streamline making. ‘We are looking forward to developing and expanding this strategic partnership in the years to come as we make an effort to achieve the goals we set for ourselves in our Vision 2015.